Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...

Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...

Regeneron Pharmaceuticals has shared positive results from a late-stage trial of Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery. The phase 3 ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) reported positive results from the Phase 3 C-POST trial, which showed that adjuvant treatment with PD-1 inhibitor Libtayo led to a statistically ...

Regeneron Pharmaceuticals, Inc. announced positive results from the phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 inhibitor Libtayo (cemiplimab) led to a statistically ...

The C-POST study involved 415 patients who were randomized to receive either Libtayo or a placebo for up to 48 weeks. The primary measure of success, disease-free survival (DFS), showed ...

Additionally, the success of Libtayo in the treatment of cutaneous squamous cell carcinoma further supports the optimistic outlook. These factors collectively contribute to the positive assessment ...

The C-POST study involved 415 patients who were randomized to receive either Libtayo or a placebo for up to 48 weeks. The primary measure of success, disease-free survival (DFS), showed significant ...